Cost‐Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step‐Up Treatment of Childhood Asthma
This study's findings are aligned with previous evidence on the economic value of ICS/LABA combinations, which found similar cost-effectiveness ratios for ICS/LABA therapies within accepted thresholds. Our probabilistic perspective supports FSC's potential as a feasible option in clinical practice for achieving better asthma control in children.
Authors
- J SANCHEZ
- Jefferson Antonio Buendía (ORCID: https://orcid.org/0000-0003-2404-6612)
Institutions
- Universidad de Antioquia (CO)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/ppul.71244
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00